Center-Authored Papers

Filters: Keyword is Granulocyte Colony-Stimulating Factor  [Clear All Filters]
A
Aapro MS, Bohlius J, Cameron DA, Dal Lago L, Donnelly PJ, Kearney N, Lyman GH, Pettengell R, Tjan-Heijnen VC, Walewski J et al..  2011.  2010 update of EORTC guidelines for the use of granulocyte-colony stimulating factor to reduce the incidence of chemotherapy-induced febrile neutropenia in adult patients with lymphoproliferative disorders and solid tumours.. European journal of cancer (Oxford, England : 1990). 47(1):8-32. Abstract
Aapro M, Schwenkglenks M, Lyman GH, Lopez Pousa A, Lawrinson S, Skacel T, Bacon P, von Minckwitz G.  2010.  Pegfilgrastim primary prophylaxis vs. current practice neutropenia management in elderly breast cancer patients receiving chemotherapy.. Critical reviews in oncology/hematology. 74(3):203-10. Abstract
Aapro MS, Cameron DA, Pettengell R, Bohlius J, Crawford J, Ellis M, Kearney N, Lyman GH, Tjan-Heijnen VC, Walewski J et al..  2006.  EORTC guidelines for the use of granulocyte-colony stimulating factor to reduce the incidence of chemotherapy-induced febrile neutropenia in adult patients with lymphomas and solid tumours.. European journal of cancer (Oxford, England : 1990). 42(15):2433-53. Abstract
Adams JR, Lyman GH, Djubegovic B, Feinglass J, Bennett CL.  2002.  G-CSF as prophylaxis of febrile neutropenia in SCLC.. Expert opinion on pharmacotherapy. 3(9):1273-81. Abstract
Adams VR, Lyman GH.  2000.  Interactive discussion on chemotherapy-related adverse events.. Pharmacotherapy. 20(7 Pt 2):121S-125S.
Arango HA, Kalter CS, Decesare SL, Fiorica JV, Lyman GH, Spellacy WN.  1994.  Management of chemotherapy in a pregnancy complicated by a large neuroblastoma.. Obstetrics and gynecology. 84(4 Pt 2):665-8. Abstract
B
Balducci L, Lyman GH.  2001.  Patients aged > or = 70 are at high risk for neutropenic infection and should receive hemopoietic growth factors when treated with moderately toxic chemotherapy.. Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 19(5):1583-5.
Bensinger WI.  2012.  Allogeneic transplantation: peripheral blood vs. bone marrow.. Current opinion in oncology. 24(2):191-196. Abstract
Bonham L, Palmer T, Miller AD.  1996.  Prolonged expression of therapeutic levels of human granulocyte colony-stimulating factor in rats following gene transfer to skeletal muscle.. Human gene therapy. 7(12):1423-9. Abstract
Borthakur G, Kantarjian H, Wang X, Plunkett WK, Gandhi VV, Faderl S, Garcia-Manero G, Ravandi F, Pierce S, Estey EH.  2008.  Treatment of core-binding-factor in acute myelogenous leukemia with fludarabine, cytarabine, and granulocyte colony-stimulating factor results in improved event-free survival.. Cancer. 113(11):3181-5. Abstract
Burroughs L, Mielcarek M, Little M-T, Bridger G, Macfarland R, Fricker S, Labrecque J, Sandmaier BM, Storb R.  2005.  Durable engraftment of AMD3100-mobilized autologous and allogeneic peripheral-blood mononuclear cells in a canine transplantation model.. Blood. 106(12):4002-8. Abstract
C
Clark OAC, Lyman G, Castro AA, Clark LGO, Djulbegovic B.  2003.  Colony stimulating factors for chemotherapy induced febrile neutropenia.. The Cochrane database of systematic reviews. (3):CD003039. Abstract
Cosler LE, Eldar-Lissai A, Culakova E, Kuderer NM, Dale D, Crawford J, Lyman GH.  2007.  Therapeutic use of granulocyte colony-stimulating factors for established febrile neutropenia: effect on costs from a hospital perspective.. PharmacoEconomics. 25(4):343-51. Abstract
Crawford J, Ozer H, Stoller R, Johnson D, Lyman G, Tabbara I, Kris M, Grous J, Picozzi V, Rausch G.  1991.  Reduction by granulocyte colony-stimulating factor of fever and neutropenia induced by chemotherapy in patients with small-cell lung cancer.. The New England journal of medicine. 325(3):164-70. Abstract
Crawford J, Armitage J, Balducci L, Bennett C, Blayney DW, Cataland SR, Dale DC, Demetri GD, Erba HP, Foran J et al..  2009.  Myeloid growth factors.. Journal of the National Comprehensive Cancer Network : JNCCN. 7(1):64-83.
Crawford J, Althaus B, Armitage J, Blayney DW, Cataland S, Dale DC, Demetri GD, Foran J, Heaney ML, Htoy S et al..  2005.  Myeloid growth factors clinical practice guidelines in oncology.. Journal of the National Comprehensive Cancer Network : JNCCN. 3(4):540-55.
D
Dugan MJ, Maziarz RT, Bensinger WI, Nademanee A, Liesveld J, Badel K, Dehner C, Gibney C, Bridger G, Calandra G.  2010.  Safety and preliminary efficacy of plerixafor (Mozobil) in combination with chemotherapy and G-CSF: an open-label, multicenter, exploratory trial in patients with multiple myeloma and non-Hodgkin's lymphoma undergoing stem cell mobilization.. Bone marrow transplantation. 45(1):39-47. Abstract
E
Eldar-Lissai A, Cosler LE, Culakova E, Lyman GH.  2008.  Economic analysis of prophylactic pegfilgrastim in adult cancer patients receiving chemotherapy.. Value in health : the journal of the International Society for Pharmacoeconomics and Outcomes Research. 11(2):172-9. Abstract
G
Goff BA, Holmberg L, Veljovich D, Kurland BF.  2008.  Treatment of recurrent or persistent platinum-refractory ovarian, fallopian tube or primary peritoneal cancer with gemcitabine and topotecan: a phase II trial of the Puget Sound Oncology Consortium.. Gynecologic oncology. 110(2):146-51. Abstract
Griffiths RI, Barron RL, Gleeson ML, Danese MD, O'Hagan A, Chia VM, Legg JC, Lyman GH.  2012.  Granulocyte-colony stimulating factor use and medical costs after initial adjuvant chemotherapy in older patients with early-stage breast cancer.. PharmacoEconomics. 30(2):103-18. Abstract
H
Hirsch BR, Lyman GH.  2012.  Pharmacoeconomics of the myeloid growth factors: a critical and systematic review.. PharmacoEconomics. 30(6):497-511. Abstract
Huston A, Lyman GH.  2007.  Agents under investigation for the treatment and prevention of neutropenia.. Expert opinion on investigational drugs. 16(11):1831-40. Abstract
I
Inamoto Y, Flowers MED, Appelbaum FR, Carpenter PA, Deeg HJ, Furlong T, Kiem H-P, Mielcarek M, Nash RA, Storb R et al..  2011.  A retrospective comparison of tacrolimus versus cyclosporine with methotrexate for immunosuppression after allogeneic hematopoietic cell transplantation with mobilized blood cells.. Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation. 17(7):1088-92. Abstract
K
Koeberl DD, Bonham L, Halbert CL, Allen JM, Birkebak T, Miller AD.  1999.  Persistent, therapeutically relevant levels of human granulocyte colony-stimulating factor in mice after systemic delivery of adeno-associated virus vectors.. Human gene therapy. 10(13):2133-40. Abstract
Kuhn E, Whiteaker JR, Mani DR, Jackson AM, Zhao L, Pope ME, Smith D, Rivera KD, Anderson LN, Skates SJ et al..  2012.  Interlaboratory evaluation of automated, multiplexed peptide immunoaffinity enrichment coupled to multiple reaction monitoring mass spectrometry for quantifying proteins in plasma.. Molecular & cellular proteomics : MCP. 11(6):M111.013854. Abstract